Technical Analysis for PTN - Palatin Technologies, Inc.

Grade Last Price % Change Price Change
grade F 0.4 -2.82% -0.01
PTN closed down 2.82 percent on Monday, August 21, 2017, on 71 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Flat
See historical PTN trend table...

Date Alert Name Type % Chg
Aug 21 Fell Below 50 DMA Bearish 0.00%
Aug 21 Doji - Bullish? Reversal 0.00%
Aug 18 Crossed Above 50 DMA Bullish -2.82%
Aug 17 Bearish Engulfing Bearish 0.50%
Aug 16 Fell Below 50 DMA Bearish -1.23%

Older signals for PTN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Get Started for Free!
Basic chart:

Profile
Palatin Technologies, Inc., a biopharmaceutical company, engages in the development of peptide therapeutics for the treatment of diseases. Its drug development programs include Bremelanotide, a peptide melanocortin receptor agonist that is in Phase IIb clinical trials for the treatment of female sexual dysfunction; and PL-3994, a peptide mimetic natriuretic peptide receptor A agonist, which is in Phase I clinical trials for the treatment of cardiovascular and pulmonary indications, as well as melanocortin receptor-based compounds for treatment of obesity. The company was founded in 1986 and is based in Cranbury, New Jersey.
Is PTN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
May 16 Edited Transcript of PTN earnings conference call or presentation 16-May-17 3:00pm GMT
May 16 Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on May 16, 2017
May 11 Palatin Technologies, Inc. to Report Third Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on May 16, 2017
Mar 31 Palatin Technologies to Present at The MicroCap Conference on April 4th at 1:00 PM ET in New York City at the Essex House
Mar 20 Palatin Technologies Receives Notice of Allowance on Bremelanotide Methods of Use Patent for Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women
Mar 9 Palatin Technologies To Present At The 29th Annual ROTH Conference
Feb 27 AMAG and Palatin Announce Rekynda™ Data Presentations at the International Society for the Study of Women’s Sexual Health Annual Meeting
Feb 22 Palatin Technologies, Inc. :PTN-US: Earnings Analysis: Q2, 2017 By the Numbers
Feb 16 AMAG Pharmaceuticals Inks $60M Drug Deal
Feb 9 Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on February 9, 2017
See more PTN news...
Indicators
Indicator Value
52 Week High 0.9
52 Week Low 0.2851
Average Volume 799,473
200-Day Moving Average 0.4291
50-Day Moving Average 0.4093
20-Day Moving Average 0.4128
10-Day Moving Average 0.4017
Average True Range 0.0187
ADX 5.55
+DI 26.92
-DI: 30.77
Chandelier Exit (Long, 3 ATRs) 0.4039
Chandelier Exit (Short, 3 ATRs) 0.4381
Upper Bollinger Band 0.4407
Lower Bollinger Band 0.3849
Percent B (%b) 0.27
Bandwidth 0.135174
MACD Line -0.0046
MACD Signal Line -0.003
MACD Histogram -0.0016